Low dose of acetylsalicylic acid and oxidative stress-mediated endothelial dysfunction in diabetes: a short-term evaluation

作者: Eliezer Joseph Tassone , Maria Perticone , Angela Sciacqua , Simona Fortunata Mafrici , Chiara Settino

DOI: 10.1007/S00592-014-0629-4

关键词:

摘要: Current guidelines suggest the use of low doses acetylsalicylic acid (ASA) for patients with diabetes mellitus (DM) in primary prevention. However, evidences demonstrating beneficial effect ASA prevention are conflicting. In this pilot study, we evaluated a group diabetic patients, prevention, impact treatment on oxidative stress and vascular function. We enrolled 22 newly diagnosed without any previous clinical evidence cardiovascular disease, to receive, (100 mg/daily). tested, basal condition, after 4 weeks administration pharmacological washout, endothelial function, assessed by semipletysmographic method, measuring main parameters related it. As expected, treatment, induced significant reduction plasma thromboxane-A2, as consequence cyclooxygenase-1 inhibition. By contrast, significantly increased urine 8-iso-PGF2α, well-known prothrombotic molecule, parallel an increase NOX2 levels. The enhancement pathway is associated impairment vasodilation, reactive hyperemia index (RHI). washout reverted all condition. Our findings that utilization causes burden impairing Present data, if confirmed larger population, could permanently discourage DM.

参考文章(29)
R. P. Raghavan, D. W. Laight, M. H. Cummings, Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function International Journal of Clinical Practice. ,vol. 68, pp. 271- 277 ,(2014) , 10.1111/IJCP.12310
Francesca Santilli, Luciana Mucci, Giovanni Davì, TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus Internal and Emergency Medicine. ,vol. 6, pp. 203- 212 ,(2011) , 10.1007/S11739-010-0440-3
Jeffrey L. Anderson, Overview of patency as an end point of thrombolytic therapy American Journal of Cardiology. ,vol. 68, pp. 11- 16 ,(1991) , 10.1016/0002-9149(91)90300-A
Pasquale Pignatelli, Roberto Carnevale, Daniele Pastori, Roberto Cangemi, Laura Napoleone, Simona Bartimoccia, Cristina Nocella, Stefania Basili, Francesco Violi, Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2 Circulation. ,vol. 126, pp. 92- 103 ,(2012) , 10.1161/CIRCULATIONAHA.112.095554
Ivan Presta, E. Joseph Tassone, Francesco Andreozzi, Maria Perticone, Angela Sciacqua, Irma Laino, Donatella Musca, Francesco Martino, Giorgio Sesti, Francesco Perticone, Angiotensin II type 1 receptor, but no type 2 receptor, interferes with the insulin-induced nitric oxide production in HUVECs Atherosclerosis. ,vol. 219, pp. 463- 467 ,(2011) , 10.1016/J.ATHEROSCLEROSIS.2011.08.042
P. Ferroni, S. Basili, A. Falco, G. Davi, Platelet activation in type 2 diabetes mellitus Journal of Thrombosis and Haemostasis. ,vol. 2, pp. 1282- 1291 ,(2004) , 10.1111/J.1538-7836.2004.00836.X
Jeffrey S. Berger, Maria C. Roncaglioni, Fausto Avanzini, Ierta Pangrazzi, Gianni Tognoni, David L. Brown, Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men JAMA. ,vol. 295, pp. 306- 313 ,(2006) , 10.1001/JAMA.295.3.306
Kjell S. Sakariassen, Eti A. Femia, Federico M. Daray, Gian M. Podda, Cristina Razzari, Mariateresa Pugliano, Andrea E. Errasti, Arnaldo R. Armesto, Wanda Nowak, Pēteris Alberts, Jean-Philippe Meyer, Alexandra S. Sorensen, Marco Cattaneo, Rodolfo P. Rothlin, EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin Thrombosis Research. ,vol. 130, pp. 746- 752 ,(2012) , 10.1016/J.THROMRES.2012.08.309
Hisao Ogawa, Masafumi Nakayama, Takeshi Morimoto, Shiro Uemura, Masao Kanauchi, Naofumi Doi, Hideaki Jinnouchi, Seigo Sugiyama, Yoshihiko Saito, Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators, None, Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 DiabetesA Randomized Controlled Trial JAMA. ,vol. 300, pp. 2134- 2141 ,(2008) , 10.1001/JAMA.2008.623